Cosmo licenses Rifamycin MMX to Dr Falk
Italy's Cosmo Pharmaceuticals SpA has licensed Rifamycin MMX (CB-01-11) to German drugmaker Dr Falk Pharma GmbH, allowing the latter to market the broad-spectrum antibiotic in Europe (excluding Italy) and Australia. Financial terms were not disclosed.
The semi-synthetic antibiotic is not systemically absorbed when taken orally. Through the use of Cosmo's MMX technology, which delivers the active ingredient into the colon, bacteria in the upper gastrointestinal tract that are important for vitamin synthesis are not sterilized.
Given that it is practically not absorbed, CB-01-11 is potentially also applicable for the treatment of long-term recurring infections in the colon.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze